Clinical Trial Update: Gene Therapy for Children With CLN3 Batten Disease [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 gene therapy trial for children with CLN3 Batten disease, sponsored by Alcyone Therapeutics, is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Batten Disease Cln3 Type

Drugs mentioned

• ALCYONE CLN3 gene therapy

Snippet

Sponsor: Alcyone Therapeutics, Inc | Conditions: CLN3, Batten Disease | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING